Sanofi (SNY)

Sanofi (SNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.

The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.

The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents b...

AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will ...

The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.

If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.

If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.